OB/GYN Clinical Alert – May 1, 2024

Novel Combined Oral Contraceptives and VTE Risk: What Do We Know?

Recently, novel combined oral contraceptives containing estradiol valerate-dienogest, estetrol-drospirenone, and 17-beta estradiol with nomegestrol acetate have been released. Whether these types of estrogen are safer than ethinyl estradiol formulations in terms of venous thromboembolism risk is unknown.

New Guidelines on p16/Ki67 Dual Stain for Triage of HPV-Positive Cervical Cancer Screening Tests

This article outlines national consensus guidelines for the use of p16/Ki67 dual stain for triage of human papillomavirus-positive cervical cancer screening tests.

Medications for OUD in the First Trimester and Congenital Malformation Risk

In this large, retrospective cohort study of births covered by Medicaid from 2000-2018, the authors used linked Medicaid use data to compare 9,514 pregnancies with buprenorphine exposure and 3,846 with methadone exposure in the first trimester. After adjusting for relevant confounders, the risk of major congenital malformation was lower for buprenorphine-exposed infants compared to methadone-exposed infants (risk ratio, 0.82; 95% confidence interval, 0.69-0.97), although rates overall remained low (50.9 per 1,000 for buprenorphine and 60.6 per 1,000 for methadone).

Supplemental Calcium Therapy for the Prevention of Preeclampsia and Preterm Birth

In pregnancy, calcium supplementation was well tolerated and reduced the risk of preeclampsia and preterm birth, with no significant differences observed between low-dose and high-dose supplementation.